Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice

2010/10/07 by Tao Yu, Chunhong Liu, Pavel Belichenko +20 · 25 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Down syndrome and intellectual disability research #Genetics and Neurodevelopmental Disorders #Congenital heart defects research

paper · doi:10.1016/j.brainres.2010.09.107

Cited by

• The use of mouse models to understand and improve cognitive deficits in Down syndrome. [europepmc]
• Down syndrome: searching for the genetic culprits. [europepmc]
• Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling Down syndrome. [europepmc]
• Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. [europepmc]
• Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations. [europepmc]
• Down Syndrome Cognitive Phenotypes Modeled in Mice Trisomic for All HSA 21 Homologues. [europepmc]
• Sex differences in protein expression in the mouse brain and their perturbations in a model of Down syndrome. [europepmc]
• Absence of Prenatal Forebrain Defects in the Dp(16)1Yey/+ Mouse Model of Down Syndrome. [europepmc]
• A Syntenic Cross Species Aneuploidy Genetic Screen Links RCAN1 Expression to β-Cell Mitochondrial Dysfunction in Type 2 Diabetes. [europepmc]
• DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome. [europepmc]
• Mouse models of Down syndrome: gene content and consequences. [europepmc]
• The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome. [europepmc]
• Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome. [europepmc]
• The burden of trisomy 21 disrupts the proteostasis network in Down syndrome. [europepmc]
• Rodent models in Down syndrome research: impact and future opportunities. [europepmc]
• Dysregulation of neurotrophin signaling in the pathogenesis of Alzheimer disease and of Alzheimer disease in Down syndrome. [europepmc]
• Nrf2 stabilization prevents critical oxidative damage in Down syndrome cells. [europepmc]
• Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A. [europepmc]
• OLIG2 Drives Abnormal Neurodevelopmental Phenotypes in Human iPSC-Based Organoid and Chimeric Mouse Models of Down Syndrome. [europepmc]
• Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors. [europepmc]
• JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome. [europepmc]
• Trisomy 21-induced dysregulation of microglial homeostasis in Alzheimer's brains is mediated by USP25. [europepmc]
• Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model. [europepmc]
• USP25 inhibition ameliorates Alzheimer's pathology through the regulation of APP processing and Aβ generation. [europepmc]
• Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model. [europepmc]